Inspired by the above exciting clinical findings of a concurrent increase in SLC25A22 and PD‐1 expression accompanied by a reduction in CD8+ T‐cell cytotoxicity in patients with CSCC, as well as the enrichment of SLC25A22 in the high PD‐L1 expression CSCC patients, we proposed that targeting the glutamine metabolism transporter SLC25A22 might have the potential to enhance CD8+ T‐cell cytotoxicity and reduce PD‐1 expression, thereby improving the efficacy of anti‐PD‐1 therapy, especially for high PD‐L1 expression CSCC patients. Here, SLC25A22 is linked to skin squamous cell carcinoma.